Ethical issues in Alzheimer’s disease research involving human subjects

As we aggressively pursue research to cure and prevent Alzheimer’s disease, we encounter important ethical challenges. None of these challenges, if handled thoughtfully, would pose insurmountable barriers to research. But if they are ignored, they could slow the research process, alienate potential...

Full description

Saved in:  
Bibliographic Details
Main Author: Davis, S. (Author)
Format: Electronic Article
Language:English
Check availability: HBZ Gateway
Journals Online & Print:
Drawer...
Fernleihe:Fernleihe für die Fachinformationsdienste
Published: BMJ Publ. 2017
In: Journal of medical ethics
Year: 2017, Volume: 43, Issue: 12, Pages: 852-856
Online Access: Volltext (JSTOR)
Volltext (lizenzpflichtig)
Volltext (lizenzpflichtig)

MARC

LEADER 00000caa a22000002 4500
001 1816156930
003 DE-627
005 20230428063452.0
007 cr uuu---uuuuu
008 220908s2017 xx |||||o 00| ||eng c
024 7 |a 10.1136/medethics-2016-103392  |2 doi 
035 |a (DE-627)1816156930 
035 |a (DE-599)KXP1816156930 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 1  |2 ssgn 
100 1 |a Davis, S.  |e VerfasserIn  |4 aut 
245 1 0 |a Ethical issues in Alzheimer’s disease research involving human subjects 
264 1 |c 2017 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
520 |a As we aggressively pursue research to cure and prevent Alzheimer’s disease, we encounter important ethical challenges. None of these challenges, if handled thoughtfully, would pose insurmountable barriers to research. But if they are ignored, they could slow the research process, alienate potential study subjects and do damage to research recruits and others. These challenges are (1) the necessity of very large cohorts of research subjects, recruited for lengthy studies, probably ending only in the subjects’ death; (2) the creation of cohorts of ’study ready' volunteers, many of whom will be competent to consent at the beginning of the process, but move into cognitive impairment later; (3) reliance on adaptive trial design, creating challenges for informed consent, equipoise and justice; (4) the use of biomarkers and predictive tests that describe risk rather than certainty, and that can threaten participants’ welfare if the information is obtained by insurance companies or long-term care providers; (5) the use of study partners that creates unique risks of harm to the relationship of subject and study partner. We need greater attention, at all levels, to these complex ethical issues. Work on these issues should be included in research plans, from the federal to the local, and should be supported through NIH in the same way that it supported work on the ethical, legal and social implications of genetic research. 
773 0 8 |i Enthalten in  |t Journal of medical ethics  |d London : BMJ Publ., 1975  |g 43(2017), 12, Seite 852-856  |h Online-Ressource  |w (DE-627)323607802  |w (DE-600)2026397-1  |w (DE-576)260773972  |x 1473-4257  |7 nnns 
773 1 8 |g volume:43  |g year:2017  |g number:12  |g pages:852-856 
856 |3 Volltext  |u http://www.jstor.org/stable/26879634  |x JSTOR 
856 4 0 |u https://doi.org/10.1136/medethics-2016-103392  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u http://jme.bmj.com/content/43/12/852.abstract  |x Verlag  |z lizenzpflichtig  |3 Volltext 
935 |a mteo 
936 u w |d 43  |j 2017  |e 12  |h 852-856 
951 |a AR 
ELC |a 1 
ITA |a 1  |t 1 
LOK |0 000 xxxxxcx a22 zn 4500 
LOK |0 001 4185610874 
LOK |0 003 DE-627 
LOK |0 004 1816156930 
LOK |0 005 20220908053716 
LOK |0 008 220908||||||||||||||||ger||||||| 
LOK |0 035   |a (DE-Tue135)IxTheo#2022-08-03#5F13EBC74455F896814464440DCA3D7C3A0421C6 
LOK |0 040   |a DE-Tue135  |c DE-627  |d DE-Tue135 
LOK |0 092   |o n 
LOK |0 852   |a DE-Tue135 
LOK |0 852 1  |9 00 
LOK |0 866   |x JSTOR#http://www.jstor.org/stable/26879634 
LOK |0 935   |a ixzs  |a ixrk  |a zota 
OAS |a 1  |b inherited from superior work 
ORI |a SA-MARC-ixtheoa001.raw